{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:33:18Z","timestamp":1773268398614,"version":"3.50.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1-AI068613"],"award-info":[{"award-number":["UM1-AI068613"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1-AI068617"],"award-info":[{"award-number":["UM1-AI068617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1-AI068619"],"award-info":[{"award-number":["UM1-AI068619"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Daily oral tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) is a safe and effective intervention for HIV preexposure prophylaxis (PrEP). We evaluated the performance of a qualitative assay that detects 20 antiretroviral (ARV) drugs (multidrug assay) in assessing recent PrEP exposure (detection limit, 2 to 20 ng\/ml). Samples were obtained from 216 Black men who have sex with men (208 HIV-uninfected men and 8 seroconverters) who were enrolled in a study in the United States evaluating the acceptability of TDF-FTC PrEP (165 of the uninfected men and 5 of the seroconverters accepted PrEP). Samples from 163 of the 165 HIV-uninfected men who accepted PrEP and samples from all 8 seroconverters were also tested for tenofovir (TFV) and FTC using a quantitative assay (detection limit for both drugs, 0.31 ng\/ml). HIV drug resistance was assessed in seroconverter samples. The multidrug assay detected TFV and\/or FTC in 3 (1.4%) of the 208 uninfected men at enrollment, 84 (40.4%) of the 208 uninfected men at the last study visit, and 1 (12.5%) of the 8 seroconverters. No other ARV drugs were detected. The quantitative assay confirmed all positive results from the multidrug assay and detected TFV and\/or FTC in 9 additional samples (TFV range, 0.65 to 16.5 ng\/ml; FTC range, 0.33 to 14.6 ng\/ml). Resistance mutations were detected in 4 of the 8 seroconverter samples. The multidrug assay had 100% sensitivity and specificity for detecting TFV and FTC at drug concentrations consistent with daily PrEP use. The quantitative assay detected TFV and FTC at lower levels, which also might have provided protection against HIV infection.<\/jats:p>","DOI":"10.1128\/aac.02743-16","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:55:26Z","timestamp":1493081726000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073"],"prefix":"10.1128","volume":"61","author":[{"given":"Yinfeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Piwowar-Manning","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geetha","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Breaud","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin A.","family":"Cloherty","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics, Abbott Park, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Emel","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Rose","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hightow-Weidman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Siegel","sequence":"additional","affiliation":[{"name":"Department of Medicine, George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon D.","family":"Fields","sequence":"additional","affiliation":[{"name":"School of Health Professions, New York Institute of Technology, Old Westbury, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"Wheeler","sequence":"additional","affiliation":[{"name":"University at Albany-State University of New York School of Social Welfare, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Eshleman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-015-0850-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_3_9_2","unstructured":"U.S. Food and Drug Administration. 2012. FDA approves first drug for reducing the risk of sexually acquired HIV infection. https:\/\/wayback.archive-it.org\/7993\/20170112032741\/http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312210.htm."},{"key":"e_1_3_3_10_2","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en."},{"key":"e_1_3_3_11_2","volume-title":"Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142014: a clinical practice guideline","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. 2014. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142014: a clinical practice guideline. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/hiv\/pdf\/PrEPguidelines2014.pdf."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-012-0141-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0182"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055013"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300951"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000172"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00761-07"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.03.016"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000633"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140074"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit672"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001229"},{"key":"e_1_3_3_24_2","unstructured":"Wheeler\nDP FieldsS NelsonLE WiltonL Hightow-WeidmanL ShoptawS MagnusM BeauchampG WatkinsP MayerKH. 2016. HPTN 073: PrEP uptake and use by Black men who have sex with men in 3 US cities abstr 883LB. Conf Retroviruses Opportunistic Infect Boston MA. http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2016\/883LB.pdf."},{"key":"e_1_3_3_25_2","first-page":"172","article-title":"HIV type 1 integrase inhibitors: from basic research to clinical implications","volume":"10","author":"Jegede O","year":"2008","unstructured":"Jegede O BabuJ Di SantoR McCollDJ WeberJ Quinones-MateuM. 2008. HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Rev10:172\u2013189.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.13.8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0172-7"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/339074"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit390"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-1-201301010-00004"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.139"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-014-0122-8"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02743-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02743-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:05:29Z","timestamp":1645477529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02743-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1128\/AAC.02743-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02743-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"2016-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02743-16"}}